<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatrics. Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Pediatrics. Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Педиатрия. Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2658-6630</issn><issn publication-format="electronic">2658-6622</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100632</article-id><article-id pub-id-type="doi">10.26442/26586630.2021.4.201348</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Polyunsaturated fatty acids: omega-3 and omega-6 and nonalcoholic fatty liver disease</article-title><trans-title-group xml:lang="ru"><trans-title>Полиненасыщенные жирные кислоты: омега-3 и омега-6 и неалкогольная жировая болезнь печени</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5684-7575</contrib-id><name-alternatives><name xml:lang="en"><surname>Berezhnaya</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Бережная</surname><given-names>Ирина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. педиатрии</p></bio><email>berezhnaya-irina26@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4200-4598</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakharova</surname><given-names>Irina N.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>Ирина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. педиатрии</p></bio><email>zakharova-rmapo@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7994-3751</contrib-id><name-alternatives><name xml:lang="en"><surname>Simakova</surname><given-names>Mariia A.</given-names></name><name xml:lang="ru"><surname>Симакова</surname><given-names>Мария Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирант каф. педиатрии</p></bio><email>simakova131@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sgibneva</surname><given-names>Aleksandra I.</given-names></name><name xml:lang="ru"><surname>Сгибнева</surname><given-names>Александра Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор каф. педиатрии</p></bio><email>zakharova-rmapo@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2021</year></pub-date><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>335</fpage><lpage>340</lpage><history><date date-type="received" iso-8601-date="2022-02-13"><day>13</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-02-13"><day>13</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://pediatria.orscience.ru/2658-6630/article/view/100632">https://pediatria.orscience.ru/2658-6630/article/view/100632</self-uri><abstract xml:lang="en"><p>The history of the study of polyunsaturated fatty acids (PUFAs) began over 100 years ago. In 1909. P. Hartley isolated arachidonic acid. Later, 21 years later, Burr and Burr in 1930 showed its positive effect on the growth and development of rats. The important thing about this work was that after reintroduction of PUFAs into the diet of rodents, body functions began to recover. It took over 60 years from the time of the discovery of arachidonic acid to prove its effect on the cardiovascular system. Today, research into the effects of long-chain PUFAs on human health, intelligence, the immune system, neuronal connections, the course of pregnancy and infant health has led to recommendations for the widespread use of foods or supplements containing omega-3 PUFAs. Unbalanced diets in children and adolescents, selective appetite, and eating disorders lead to the development of deficit conditions, cognitive impairment, obesity, and metabolic syndrome with liver damage. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are asymptomatic in the early stages, but it is during this period that the prognosis in children can be changed. This article reviews international recommendations for the integrated use of long-chain PUFAs in the treatment of NAFLD and NASH in children. Supplementation of the diet with high-quality purified fish oil replenishes the requirement, improves disease prognosis, reduces insulin resistance and the level of liver fibrosis in patients with NAFLD and NASH.</p></abstract><trans-abstract xml:lang="ru"><p>История изучения полиненасыщенных жирных кислот (ПНЖК) началась более 100 лет назад. В 1909 г. P. Hartley выделил арахидоновую кислоту. Позже, через 21 год, Burr и Burr в 1930 г. показали положительное ее влияние на рост и развитие крыс. Важным в этой работе явилось то, что после повторного введения ПНЖК в рацион питания грызунов функции организма стали восстанавливаться. От момента открытия арахидоновой кислоты до доказательства ее влияния на сердечно-сосудистую систему прошло еще более 60 лет. Сегодня изучение влияния длинноцепочечных ПНЖК на здоровье человека, его интеллект, иммунную систему, связи между нейронами, течение беременности и здоровье новорожденных привело к рекомендациям широкого использования пищевых продуктов или биологических добавок, содержащих омега-3-ПНЖК. Несбалансированный пищевой рацион детей и подростков, избирательность аппетита, нарушение пищевого поведения приводят к развитию дефицитных состояний, когнитивных нарушений, ожирения и метаболического синдрома с поражением печени. Неалкогольная жировая болезнь печени (НАЖБП) и неалкогольный стеатогепатит (НАСГ) на ранних стадиях протекают бессимптомно, но именно в этот период можно изменить прогноз заболевания у детей. В статье рассмотрены международные рекомендации комплексного применения длинноцепочечных ПНЖК в комплексной терапии НАЖБП и НАСГ у детей. Сапплементация пищевого рациона введением очищенного высококачественного рыбьего жира восполняет потребность, улучшает прогноз заболевания, снижает инсулинорезистентность и уровень фиброза печени у пациентов с НАЖБП и НАСГ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>children</kwd><kwd>liver</kwd><kwd>obesity</kwd><kwd>metabolic syndrome</kwd><kwd>polyunsaturated fatty acids</kwd><kwd>omega-3-polyunsaturated fatty acids</kwd><kwd>omega-6-polyunsaturated fatty acids</kwd><kwd>nonalcoholic fatty liver disease</kwd><kwd>nonalcoholic steatohepatitis</kwd><kwd>dietary supplements</kwd><kwd>fish oil</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>печень</kwd><kwd>ожирение</kwd><kwd>метаболический синдром</kwd><kwd>полиненасыщенные жирные кислоты</kwd><kwd>омега-3-полиненасыщенные жирные кислоты</kwd><kwd>омега-6-полиненасыщенные жирные кислоты</kwd><kwd>неалкогольная жировая болезнь печени</kwd><kwd>неалкогольный стеатогепатит</kwd><kwd>сапплементация пищевого рациона</kwd><kwd>рыбий жир</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wiktorowska-Owczarek A, Berezińska M, Nowak JZ. PUFAs: Structures, Metabolism and Functions. Adv Clin Exp Med. 2015;24(6):931-41.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Das UN. Essential Fatty acids – a review. Curr Pharm Biotechnol. 2006;7(6):467-82.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231-48.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol. 2009;77(6):937-46.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr. 2004;23:281-302.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lauritzen L, Hansen HS, Jørgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res. 2001;40(1 2):1-94.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Uauy R, Birch E, Birch D, et al. Visual and brain function measurements in studies of n-3 fatty acid requirements of infant. J Pediatr. 1992;120:168-80.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Farquharson J, Cockburn F, Patrick WA. Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet. 1992;340:810-13.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hartley P. On the nature of the fat contained in the liver, kidney and heart: Part II. J Physiol. 1909;38(5):353-74.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Smedley-Maclean I, Nunn LC. Fat-deficiency disease of rats. The effect of doses of methyl arachidonate and linoleate on fat metabolism, with a note on the estimation of arachidonic acid. Biochem J. 1940;34(6):884-902.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Holman RT. Essential fatty acids. Nutr Rev. 1958;16:33-5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Parrish CC. Essential fatty acids in aquatic food webs. In: Arts MT, Brett MT, Kainz M, editors. Lipids in Aquatic Ecosystems. 1st ed. Springer; New York, NY, USA: 2009; p. 309-26.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975;28:958-66.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bjerregaard P, Dyerberg J. Mortality from ischaemic heart disease and cerebrovascular disease in Greenland. Int J Epidemiol. 1988;17(3):514-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yashodhara BM, Umakanth S, Pappachan JM, et al. Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgrad Med J. 2009;85(1000):84-90.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kapoor B, Kapoor D, Gautam S, et al. Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits. Curr Nutr Rep. 2021;10(3):232-42.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ikeda I, Yoshida H, Tomooka M, et al. Effects of long-term feeding of marine oils with different positional distribution of eicosapentaenoic and docosahexaenoic acids on lipid metabolism, eicosanoid production, and platelet aggregation in hypercholesterolemic rats. Lipids. 1998;33(9):897-904.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids. 2003;126(1):1-27.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Koletzko B, Agostoni C, Carlson SE, et al. Long chain polyunsaturated fatty acids (LC-PUFA) and perinatal development. Acta Paediatr. 2001;90:460-4.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>McCann JC, Ames BN. Is docosahexaeboic acid, an ω-3 longchain polyunsaturated fatty acid required for development of normal brain function? Am J Clin Nutr. 2005;82:281-95.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Agostoni C. Role of long-chain polyunsaturated fatty acids in the first year of life. J Pediatr Gastroenterol Nutr. 2008;47(2):41-4.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Cockburn F. Neonatal brain and dietary lipids. Arch Dis Child. 1994;70(1):1-2.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lucas A. Breast milk and subsequent intelligence quotient in children born preterm. Lancet. 1992;339:261-4.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Захарова И.Н., Бережная И.В., Санникова Т.Н., и др. Кесарево сечение и проблемы лактации у женщин. Медицинский совет. 2018;17:22-9 [Zakharova IN, Berezhnaia IV, Sannikova TN, et al. Kesarevo sechenie i problemy laktatsii u zhenshchin. Meditsinskii sovet. 2018;17:22-9 (in Russian)].</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Innis SM. Human milk and formula fatty acids. J Pediatr. 1993;123:386-90.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15(8):511-23.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance – A review. Life Sci. 2018;203:255-67.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1226-33.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr. 2021. DOI:10.1038/s41430-021-00928-z</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97(13):e0214.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Anania C, Perla FM, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24(19):2083-94.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319-34.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Петеркова В.А., Безлепкина О.Б., Васюкова О.В., и др. Ожирение у детей. Клинические рекомендации. Российская ассоциация эндокринологов. М., 2021 [Peterkova VA, Bezlepkina OB, Vasiukova OV, et al. Ozhirenie u detei. Klinicheskie rekomendatsii. Rossiiskaia assotsiatsiia endokrinologov. Moscow, 2021 (in Russian)].</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Spooner MH, Jump DB. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Curr Opin Clin Nutr Metab Care. 2019;22(2):103-10.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Chen LH, Wang YF, Xu QH, Chen SS. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2018;37(2):516-21.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108-25.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Cunnane SC. The Canadian Society for Nutritional Sciences 1995 Young Scientist Award Lecture. Recent studies on the synthesis, beta-oxidation, and deficiency of linoleate and alpha-linolenate: are essential fatty acids more aptly named indispensable or conditionally dispensable fatty acids? Can J Physiol Pharmacol. 1996;74(6):629-39.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Тутельян В.А., Батурин А.К., Гаппаров М.Г., и др. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Методические рекомендации МР 2.3.1.2432-08. 2008; с. 14-5 [Tutel'ian VA, Baturin AK, Gapparov MG, et al. Normy fiziologicheskikh potrebnostei v energii i pishchevykh veshchestvakh dlia razlichnykh grupp naseleniia Rossiiskoi Federatsii. Metodicheskie rekomendatsii MR 2.3.1.2432-08. 2008; s. 14-5 (in Russian)].</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Dotterud CK, Storro O, Simpson MR, et al. The impact of preand postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care. BMC Public Health. 2013;13:123.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Макарова С.Г., Чумбадзе Т.Р., Поляков С.Д., и др. Персонифицированный подход к питанию детей-спортсменов: практические рекомендации. Педиатрическая фармакология. 2016;13(5):468-77 [Makarova SG, Chumbadze TR, Poliakov SD, et al. Personifitsirovannyi podkhod k pitaniiu detei-sportsmenov: prakticheskie rekomendatsii. Pediatricheskaia farmakologiia. 2016;13(5):468-77 (in Russian)]. DOI:10.15690/pf.v13i5.1642</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Panel on Dietetic Products N., Allergies (NDA). EFSA Journal. 2010;8:107.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br J Nutr. 2012;107(Suppl. 2):S159-S170.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Minziori G, Polizos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother. 2016;17(14):1937-46. DOI:10.1080/14656566.2016.1225727</mixed-citation></ref></ref-list></back></article>
